-+ 0.00%
-+ 0.00%
-+ 0.00%

StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15

Benzinga·11/11/2026 13:45:00
Listen to the news
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.